Loading...
•
Mar 31, 2023
Bausch Health Q1 2023 Earnings Report
Bausch Health's Q1 2023 performance was marked by revenue growth and advancements in its product pipeline.
Key Takeaways
Bausch Health reported a 1% increase in first-quarter revenue to $1.94 billion, with organic revenue growth of 4%. The company is progressing its mid- and late-stage pipeline and reaffirmed its full-year guidance for Bausch Health (excl. B+L) and provided full year consolidated guidance.
First-Quarter revenues reached $1.94 billion, a 1% increase reported and 4% organic growth.
Xifaxan led core product revenue growth with a 7% reported increase.
The mid- and late-stage product pipeline is advancing.
Consolidated full-year guidance provided; Bausch Health (excl. B+L) confirms 2023 guidance.
Bausch Health
Bausch Health
Bausch Health Revenue by Segment
Revenue by Segment
Bausch + Lomb/International Revenue
CapyFin.comSalix Revenue
CapyFin.comDiversified Products Revenue
CapyFin.com Forward Guidance
The Company confirmed its full year guidance for Bausch Health (excl. B+L) and is providing full year consolidated guidance as follows:
Positive Outlook
- Full year revenue range of $8.35 - $8.55 billion
- Full year Adjusted EBITDA (non-GAAP) range of $3.00 - $3.15 billion
Revenue & Expenses
Visualization of income flow from segment revenue to net income